drugset / Trial / NCT05909072

Tranexamic Acid With Microneedling in Melasma

NCT05909072

Phase 2 Unknown 27 enrolled Zagazig University
RandomizedParallel-groupSingle-blindTreatment

Summary

Topical tranexamic, a hydrophilic molecule, can't pass the lipid barriers of the stratum corneum and it's also not retained in adequate amount in the epidermis to enter the melanocytes, so there's a difficulty in the effective delivery of tranexamic acid into the melanocytes . Hyaluronic acid was proved to improve the effective delivery of tranexamic acid through loosening corneocyte packing and helping TXA entering the melanocytes and minimizing its epidermal diffusion .

Timeline

Start
2023-06
Primary completion
2023-11
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hyaluronic Acid Other / unclassified 0.5 ml
Comparator Tranexamic Acid Small molecule 1 ml Topical